{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:46Z","timestamp":1792718326478,"version":"4.5.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jaad.2017.10.043","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T20:17:07Z","timestamp":1509740227000},"page":"403-404.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients"],"prefix":"10.1016","volume":"78","author":[{"given":"Lucy Y.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany G.","family":"Craiglow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2017.10.043_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.10.043_bib2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2017.10.043_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.10.043_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0190-9622(99)70195-7","article-title":"Alopecia areata investigational assessment guidelines\u2013part II. National Alopecia Areata Foundation","volume":"40","author":"Olsen","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.10.043_bib5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1067\/mjd.2003.423","article-title":"Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis\/universalis","volume":"49","author":"Tosti","year":"2003","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217326014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217326014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:46:07Z","timestamp":1759272367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217326014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0190962217326014"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.10.043","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}